Not Yet RecruitingPhase 4

Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo

300 participantsStarted 2026-04-15

Plain-language summary

The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of routine mpox vaccination campaigns in Kinshasa, Democratic Republic of the Congo (DRC). Participants will be followed at multiple time points after vaccination in order to assess the kinetics and durability of the immune response by collection of blood samples. We plan to include approximately 150 participants vaccinated with MVA-BN and 150 participants vaccinated with LC16m8.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any person aged 18 or over at the time of giving informed consent, of any gender * Having received the MVA-BN or LC16m8 mpox vaccine as part of national vaccination campaigns * Having the capacity and willingness to give informed written consent * Agreeing to adhere to the study's follow-up schedule

What they're measuring

To estimate the seroconversion rate for neutralising antibodies against the mpox virus (MPXV) 28 days after administration of a mpox vaccine (MVA-BN or LC16m8)

Timeframe: Day 28 after inclusion

Trial details

NCT IDNCT07499739

SponsorInstitute of Tropical Medicine, Belgium

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11-15

Contact for this trial

Laurens Liesenborghs

+3232476817 lliesenborghs@itg.be

View on ClinicalTrials.gov More Mpox trials